Sanitas
Find medicine, supplier, source
⌘K
7 mapped medicines
4
Cisplatin Injection
Official shortage evidence plus one clearly constrained supplier path.
87
Carboplatin Injection
Related platinum chemotherapy with shared upstream exposure.
72
Oxaliplatin Injection
Platinum oncology medicine watched for API pressure signals.
61
Methotrexate Injection
Oncology sterile injectable with separate active ingredient constraints.
49
Ifosfamide Injection
Recent oncology shortage signal with supplier capacity pressure.
58
Pemetrexed Injection
Oncology product included as a stable comparator.
22
Saline bags
Infusion supply comparator with broad manufacturing base.
21
Platinum-based API
Contextual API pressure signal, useful but not the main action path.
shared
Platinum raw material
Upstream raw material with concentrated global mining exposure.
concentrated
Sterile injectable vial
Fill-finish capacity determines whether API can become hospital-ready supply.
capacity
Oncology API capacity
Shared active-ingredient capacity watched across sterile oncology medicines.
Borosilicate glass
Shared sterile container material with broad supplier coverage.
IV tubing resin
Commodity input for infusion sets with multiple approved sources.
Accord / Intas
FDA lists Accord presentations unavailable for GMP compliance requirements.
GMP
Eugia US
Context supplier: FDA lists unavailable presentations tied to demand increase.
demand
Fresenius Kabi
Context supplier: shipping delay reduces usable redundancy.
delay
Pfizer / Hospira
Context supplier: limited and unavailable presentations due to demand.
limited
Gland / BPI Labs
Context supplier: discontinued presentations narrow fallback capacity.
Teva
Visible supplier retained as lower-active-risk redundancy context.
Teyro / Apotex
Context supplier: discontinued presentations reduce backup supply options.
Gujarat manufacturing site
Manufacturing geography tied to the Accord / Intas supply path.
IN
South African platinum supply
Upstream concentration risk for platinum raw material, not a proven direct cause.
raw
U.S. oncology market
Clinical market where shortages force allocation decisions.
Hospital pharmacy
Downstream care setting exposed to upstream availability risk.
FDA current shortage
Primary FDA evidence confirms the active cisplatin shortage.
2026
GMP compliance constraint
The clearest actionable constraint: quality compliance limits a supplier path.
quality
Demand increase
FDA lists demand increase across multiple unavailable or limited presentations.
Shipping delay
Logistics delay further reduces usable supplier redundancy.
Discontinued presentations
Discontinued products reduce backup supply options.
2026 API shortage signal
Supporting source found by investigation, not a second urgent action path.
new
Platinum supply deficit
Market signal explains upstream fragility without claiming direct causality.
FDA carboplatin shortage
Primary source for related platinum chemotherapy shortage status.
primary
FDA oxaliplatin listing
Primary shortage database signal for related platinum chemotherapy context.
primary
ASHP oncology listings
Clinical pharmacy shortage listings for oncology sterile injectables.
clinical
Guardian injectable shortage
News analysis of generic sterile injectable manufacturing fragility.
news
FDA shortage page
Primary source for current shortage and supplier-level constraints.
primary
ASHP shortage page
Clinical shortage source for usual-ordering availability.
clinical
Axios cancer shortage
News context for rationing, delays, and generic oncology fragility.
NCCN survey article
Supports oncology-center impact statistics from the 2023 wave.
FT Intas analysis
News analysis of Intas / Accord quality failure and market fragility.
WPIC platinum deficit
Industry market evidence for platinum deficit and concentration risk.